Who are Docetaxel only's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): nab-paclitaxel，Cisplatin, Dose dense AC followed by T + trastuzumab, Paclitaxel, Carboplatin, docetaxel and cisplatin, Placebo plus Docetaxel, Paclitaxel (Pac).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/docetaxel-only.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Docetaxel only — Competitive Intelligence Brief

Docetaxel only (Docetaxel only) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane. Area: Oncology.

phase 2 Taxane Microtubules Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Docetaxel only (Docetaxel only) — Samsung Medical Center. Docetaxel is a microtubule inhibitor that binds to tubulin and prevents microtubule assembly.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Docetaxel only TARGET	Docetaxel only	Samsung Medical Center	phase 2	Taxane	Microtubules
nab-paclitaxel，Cisplatin	nab-paclitaxel，Cisplatin	Yang Jianjun, PhD	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (cisplatin)
Dose dense AC followed by T + trastuzumab	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)
Paclitaxel, Carboplatin	Paclitaxel, Carboplatin	Queensland Centre for Gynaecological Cancer	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (carboplatin)
docetaxel and cisplatin	docetaxel and cisplatin	Sanofi	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (docetaxel); DNA (cisplatin)
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane class)

Sanofi · 3 drugs in this class
Akeso · 1 drug in this class
Fourth Affiliated Hospital of Guangxi Medical University · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Central European Society for Anticancer Drug Research · 1 drug in this class
Chengdu Kanghong Biotech Co., Ltd. · 1 drug in this class
Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
Jina Pharmaceuticals Inc. · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Docetaxel only — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-only. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab